Long-Term Neurodevelopmental Effects of Prenatal Opioid Exposure
Perinatal exposure to opioids may have significant immune, neural, and behavioral effects that can alter CNS development.
Opioid Addiction
OPIOIDS
Feature Article
Latest
Opioid Overprescribing Observed Among Patients With Depression, Bipolar Disorder
Given the increased risk for opioid-related problems among patients with psychiatric diagnoses, the investigators advised a more cautious approach to prescribing that integrates expertise from mental health clinicians.
Opioid Prescribing Trends for Osteoarthritis Between 2008 and 2017
Researchers examined the incidence, prevalence and trends for opioid prescriptions in patients with osteoarthritis.
Hydromorphone-CR Exposure Increases Endocarditis Risk in PWID
Exposure to controlled-release hydromorphone, an opioid that can be abused through crushing and injection, is associated with an increased risk for infective endocarditis among people who inject drugs.
Opioid Prescribing Rates Reduced at State Level From 2010 to 2016
Prescription drug monitoring program data from individual states show a decline in opioid prescribing rates in 11 participating states from 2010 to 2016.
Few Providers Account for Large Number of Opioid Prescriptions
A small proportion of providers account for almost half of all opioid doses and about one-quarter of opioid prescriptions.
Most Patients With Opioid-Related Hospitalizations Have Chronic Conditions
Since patients with chronic diseases are often prescribed opioids, researchers sought to examine the association between opioid-related hospitalization and patients with chronic disease. Since patients with chronic diseases are often prescribed opioids, researchers sought to examine the association between opioid-related hospitalization and patients with chronic disease.
Promotion of Medications for Opioid Use Disorder Aimed at Urban, Not Rural, Prescribers
Researchers looked at data for 18,318 physicians who received opioid use disorder medication promotions, totaling $9.6 million during the study period.
FDA Panels Vote “No” on the Abuse-Deterrent Opioid Aximris XR
The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted against (2 “yes”, 24 “no”) the approval of Aximris XR
FDA Committees Vote on Novel Opioid for Chronic Low Back Pain
As a result of the vote, Nektar has decided to withdraw the New Drug Application for oxycodegol and to cease further development of the product.
Effects of Opioid Agonists on Sleep Quality in Opioid Use Disorder
Patients perception of poor sleep differ from EEG-reported results.
Want to read more?
Please login or register first to view this content.
Next post in Opioid Addiction
